ジクロキサシリン 化学特性,用途語,生産方法
効能
抗生物質, 細胞壁合成阻害薬
説明
Chemically this is 3(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl penicillin.
It differs from cloxacillin by having two chloride ions attached to
the phenyl group. It comes as oral capsules of 250 and 500 mg, and in
an injectable formulation of 500 mg and 1 g.
使用
Antibacterial.
定義
ChEBI: A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.
抗菌性
It is very highly bound to serum
protein, and its activity in the presence of human serum
in vitro is depressed to a greater extent than that of other
isoxazolylpenicillins.
一般的な説明
Dicloxacillin was synthesized by Bayer in 1965 starting with 6-aminopenicillanic acid. It is a penicillinase-stable and orally active semisynthetic penicillin and shows higher and longer serum concentrations than cloxacillin when administered orally. Dicloxacillin is used orally, either alone or in combination with ampicillin, to treat various infections, including those caused by benzylpenicillin-resistant bacteria.
薬理学
In terms of mechanism of action, antibacterial spectrum, and indications for use, it is
essentially no different than oxacillin and cloxacillin. Synonyms of this drug are diclocil,
novapen, diclex, and others.
The following type of semisynthetic penicillins that should be considered are those in
which amino acids, mainly α-aminophenylacetic or p-oxy-α-amino-phenylacetic acids,
act as the acyl radical (ampicillin, amoxacillin).
The antimicrobial spectrum of aminopenicillins is similar to penicillin G, with the
exception that they also act on a number of Gram-negative microorganisms. Both
aminopenicillins are destroyed by staphylococcus penicillinase.
薬物動態学
Oral absorption: c. 50%
C
max , 250 mg oral: 9 mg/L after 1 h
500 mg intramuscular: 14–16 mg/L after 0.5–1 h
Plasma half-life: 0.5 h
Plasma protein binding: 95–97%
Absorption
Absorption in the very young is poor and unpredictable.
Metabolism and excretion
Dicloxacillin is partly metabolized in the liver and about
10% of the circulating drug is in the form of metabolites.
Some 50–70% of a dose is excreted in the urine, about
20% as metabolites. It is eliminated both in the glomerular
filtrate and by tubular secretion, and plasma concentrations
are raised by probenecid. Parent drug and increased
proportions of metabolites accumulate in renal failure.
Elimination is increased through enhanced tubular secretion
in patients with cystic fibrosis.
副作用
Phlebitis is common after intravenous injection. Its toxicity
is otherwise similar to that of other penicillins.
Clinical uses are those of the group 3 penicillins.
ジクロキサシリン 上流と下流の製品情報
原材料
準備製品